We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA’s Complete Responses to Generic Drugmakers Continue to Outpace Fiscal 2017
FDA’s Complete Responses to Generic Drugmakers Continue to Outpace Fiscal 2017
The FDA continued to issue a larger number of complete response letters to generics manufacturers last month — dropping from a spike in October, but still higher than any single month in the previous fiscal year.